Avacta Group Plc RTQ1.F Stock
Avacta Group Plc Price Chart
Avacta Group Plc RTQ1.F Financial and Trading Overview
| Avacta Group Plc stock price | 0.46 EUR |
| Previous Close | 1.15 EUR |
| Open | 1.14 EUR |
| Bid | 1.17 EUR x N/A |
| Ask | 1.25 EUR x N/A |
| Day's Range | 1.14 - 1.14 EUR |
| 52 Week Range | 1.05 - 2.12 EUR |
| Volume | 890 EUR |
| Avg. Volume | 15 EUR |
| Market Cap | 322.88M EUR |
| Beta (5Y Monthly) | 1.55134 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.11 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
RTQ1.F Valuation Measures
| Enterprise Value | 333.45M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 33.449017 |
| Price/Book (mrq) | 16.285713 |
| Enterprise Value/Revenue | 34.544 |
| Enterprise Value/EBITDA | -13.698 |
Trading Information
Avacta Group Plc Stock Price History
| Beta (5Y Monthly) | 1.55134 |
| 52-Week Change | 0% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.12 EUR |
| 52 Week Low | 1.05 EUR |
| 50-Day Moving Average | 1.28 EUR |
| 200-Day Moving Average | 1.36 EUR |
RTQ1.F Share Statistics
| Avg. Volume (3 month) | 15 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 275.35M |
| Float | 265.13M |
| Short Ratio | N/A |
| % Held by Insiders | 34.33% |
| % Held by Institutions | 12.89% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -264.50% |
| Gross Margin | 64.15% |
| EBITDA Margin | -252.18% |
Management Effectiveness
| Return on Assets (ttm) | -22.85% |
| Return on Equity (ttm) | -132.55% |
Income Statement
| Revenue (ttm) | 9.65M EUR |
| Revenue Per Share (ttm) | 0.04 EUR |
| Quarterly Revenue Growth (yoy) | 190.19% |
| Gross Profit (ttm) | 6.19M EUR |
| EBITDA | -24343000 EUR |
| Net Income Avi to Common (ttm) | -39540000 EUR |
| Diluted EPS (ttm) | -0.18 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 41.78M EUR |
| Total Cash Per Share (mrq) | 0.15 EUR |
| Total Debt (mrq) | 62.94M EUR |
| Total Debt/Equity (mrq) | 341.38 EUR |
| Current Ratio (mrq) | 0.822 |
| Book Value Per Share (mrq) | 0.07 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -16432000 EUR |
| Levered Free Cash Flow (ttm) | -8628250 EUR |
Profile of Avacta Group Plc
| Country | Germany |
| State | N/A |
| City | Wetherby |
| Address | Thorp Arch Estate |
| ZIP | LS23 7FA |
| Phone | 44 1904 217 070 |
| Website | https://www.avacta.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 120 |
Avacta Group Plc develops cancer therapies and diagnostics in the United Kingdom, France, North America, South Korea, and rest of Asia and Europe. The company operates through Diagnostics and Therapeutics segments. It develops products based on its proprietary Affimer and pre|CISION technology platforms. The company develops AVA6000, FAPa-activated doxorubicin that is in Phase I clinical trial for treating locally advanced or metastatic-selected solid tumors; AVA3996, a tumor-targeted proteasome inhibitor based on bortezomib; AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 - PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPa. The company has a collaboration agreement with LG Chem for developing and commercializing LR19128 PD-L1 XT; and collaboration and license agreement with Avacta and Daewoong Pharmaceutical Co. Ltd. for developing AFX-001 for solid organ transplant and graft vs host Disease, and AFX-002 for multiple sclerosis. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.
Q&A For Avacta Group Plc Stock
What is a current RTQ1.F stock price?
Avacta Group Plc RTQ1.F stock price today per share is 0.46 EUR.
How to purchase Avacta Group Plc stock?
You can buy RTQ1.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Avacta Group Plc?
The stock symbol or ticker of Avacta Group Plc is RTQ1.F.
Which industry does the Avacta Group Plc company belong to?
The Avacta Group Plc industry is Biotechnology.
How many shares does Avacta Group Plc have in circulation?
The max supply of Avacta Group Plc shares is 421.89M.
What is Avacta Group Plc Price to Earnings Ratio (PE Ratio)?
Avacta Group Plc PE Ratio is now.
What was Avacta Group Plc earnings per share over the trailing 12 months (TTM)?
Avacta Group Plc EPS is -0.11 EUR over the trailing 12 months.
Which sector does the Avacta Group Plc company belong to?
The Avacta Group Plc sector is Healthcare.